Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme

Executive Summary

FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.

You may also be interested in...



Prior Bad Conduct By Pharma Companies Could Be ‘Plus Factor’ In Merger Review

Experts suggest US FTC and DOJ retrospectively assess whether a merger gives companies increased leverage with PBMs and consider how it will impact vulnerable communities. Rutger’s Michael Carrier says there should be a presumption against mergers between two large firms.

Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise

Panelists at FTC/DOJ workshop suggest new remedies to ensure pharma mergers are not anti-competitive. The commission should support scientists and ensure R&D continues, one expert says.

FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle

Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel